In our unique approach to structure-based drug discovery, Ventus uses the powerful ReSOLVE platform, leveraging distinct and proprietary technologies to target biologically validated, but difficult-to-drug proteins in important disease pathways. ReSOLVE enables us to find new pockets and better characterize known pockets, and then design new drug molecules for both.

high-value targets

We select only those targets that defy conventional approaches and have a high degree of preclinical, clinical and genetic validation for serious diseases.

unlock structure-based drug
discovery for critical targets

At the foundation of our approach, we apply structural biology and proprietary protein engineering to solve challenging target protein structures across many diseases. Ventus is uniquely structurally enabled for high-value and elusive targets in innate immune pathways of relevance for autoimmune and inflammatory diseases, as well as cancer.

APPLY our platform

Ventus’ ReSOLVE platform combines leading-edge computational chemistry technologies with unique structural biology capabilities, protein engineering, biophysics and chemistry.

potential intervention points

Using our structural biology and protein capabilities, combined with our ReSOLVE computational chemistry platform, we identify previously unknown small molecule binding pockets, enabling discovery of potent and differentiated chemical matter for new drug compounds. We also aim to better-characterize known binding pockets, to generate improved chemical matter with increased binding affinity.

Model the solvation structure around
dynamic protein conformations

We are able to accurately define the hydrocophore, or the dynamic solvation structure for the small molecule binding pockets identified via ReSOLVE. This proprietary capability leads to the most complete understanding of the physics-based parameters of small molecule and protein interaction and the highest resolution for rational drug design.

The hydrocophore allows us to understand a pocket’s druggability, shape, polarity, and functional site proximity. After extracting the hydrocophore, we conduct incredibly efficient virtual screening of billions of compounds, in the complete absence of known chemical matter. We can identify and validate diverse chemical matter for a new target in less than three months and at a fraction of the cost of traditional methods.

We have solved the virtual screening paradox. Our platform yields dozens of virtual hits with a high probability of success, instead of thousands of hits with a low success rate. Therefore, synthesizing chemical matter for experimental testing can happen in weeks, not months.